Emerging clinical data shows that GLP-1 receptor agonists (such as semaglutide and liraglutide) offer significant cardiovascular benefits for patients with atrial fibrillation (AFib). Extensive studies demonstrate that GLP-1 therapies reduce the risk of incident AFib, decrease AFib recurrence, and improve ablation outcomes—often independently of weight loss.Cardiovascular BenefitsReduced Incidence: Research presented at the American Heart Association and Heart Rhythm Society shows that GLP-1… read more
What are the potential benefits and risks of GLP-1 drugs for people with AFib?
GLP-1 receptor agonists (like semaglutide/Ozempic and liraglutide) are generating real excitement in the AFib world. Here's a breakdown of what the emerging data suggests:
Potential Benefits
- GLP-1 users may have an 18%–26% lower risk of Show Full Answer
I am trying to be not on formulary yet though. It does say less side effects and no muscle loss. So far am just maintain the 10lbs I lost while in hospital. I do only take 1 to ill instead of 2 though. Thanks for the post.
Thank you 😊